Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pentetreotide→

Pentetreotide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
138661-02-6
Molecular formula
C63H87N13O19S2
Molecular weight
1394.6 g/mol
Drug class
Somatostatin analogueDTPA-conjugated peptide radiopharmaceutical ligand
Mechanism of action
The pentetreotide peptide moiety binds somatostatin receptors, particularly subtype 2, expressed on many neuroendocrine tumour cells. When conjugated with indium-111, the radiolabel enables scintigraphic localisation of somatostatin-receptor-positive lesions.
Indications / reported uses
  • Used as the peptide component of indium In-111 pentetreotide (octreotide DTPA) for scintigraphic imaging of somatostatin-receptor-positive neuroendocrine tumours; the radiolabelled product, not unlabelled pentetreotide alone, is the diagnostic radiopharmaceutical.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/indium-in-111-pentetreotide · https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020314s012lbl.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pentetreotide Environmental Risk Assessment (ERA) (the Pentetreotide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.